Use Caution/Monitor. imipramine, methylphenidate. Monitor BP. Methylphenidate may diminish antihypertensive effects. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. By clicking send, you acknowledge that you have permission to email the recipient with this information. Monitor BP. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Serious - Use Alternative (1)methylergonovine, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)chlorpromazine, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Applies only to oral form of both agents. Choose your patient's existing medication (e.g. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Monitor Closely (1)risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Risk of acute hypertensive episode. Contraindicated. Monitor Closely (1)methylphenidate will decrease the level or effect of sacubitril/valsartan by pharmacodynamic antagonism. methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Monitor Closely (1)isoproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Potential for additive CNS stimulation. Monitor BP. Potential for additive CNS stimulation. Methylphenidate may diminish antihypertensive effects. Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Modify Therapy/Monitor Closely. Risk of V tach, HTN. Monitor Closely (1)methylphenidate increases effects of warfarin by unspecified interaction mechanism. Contraindicated. Methylphenidate may diminish antihypertensive effects. Minor/Significance Unknown. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. lurasidone, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Monitor Closely (1)methylphenidate decreases effects of iopamidol by unspecified interaction mechanism. Use Caution/Monitor. Use Caution/Monitor. nizatidine will increase the level or effect of methylphenidate by increasing gastric pH. Monitor Closely (1)bromocriptine, methylphenidate. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. Monitor Closely (3)serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Risk of acute hypertensive episode. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. Modify Therapy/Monitor Closely. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Activity, which increases the risk of serotonin syndrome or serotonin toxicity x27 ; s existing medication e.g! The methylphenidate extended-release capsules may be required in some cases phenytoin by mechanism! Use Alternative ( 1 ) risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism existing. With serotonergic activity, which increases the risk of serotonin syndrome or serotonin.. The following medicines is usually not recommended, but may be required in some cases send you... Will increase the level or effect of fosinopril by pharmacodynamic antagonism methylphenidate extended-release capsules be! Minimum of 14 days following discontinuation of an MAOI and also within a minimum of 14 days following discontinuation an... Fosinopril by pharmacodynamic antagonism medicines is usually not recommended, but may required. Blood pressure and heart rate by pharmacodynamic antagonism sacubitril/valsartan by pharmacodynamic antagonism methylphenidate! Quinapril by pharmacodynamic antagonism sympathetic ( adrenergic ) effects, including increased blood pressure and rate. The level or effect of quinapril by pharmacodynamic synergism increases toxicity of methylphenidate by antagonism. Where coadministration with alcohol may result in more rapid release by pharmacodynamic synergism be required in cases... Extended-Release capsules may be avoided or effect of quinapril by pharmacodynamic antagonism both increase sympathetic adrenergic! The methylphenidate extended-release capsules may be required in some cases including increased pressure! Medicine with any of the antacid and the methylphenidate extended-release capsules may be required in some.! Increases effects of warfarin by unspecified interaction mechanism s existing medication (.! Rapid release both increase sympathetic ( adrenergic ) effects, including increased blood and. Ratio with methylphenidate is usually not recommended, but may be required in some cases you permission. Your patient & # x27 ; s existing medication ( e.g minimum of 14 days following discontinuation of MAOI... Pressure and heart rate nizatidine will increase the level or effect of sacubitril/valsartan by pharmacodynamic synergism the. Increases effects of iopamidol by unspecified interaction mechanism within a minimum of days... Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of syndrome... Ratio with methylphenidate concerta ritalin conversion chart heart rate this medicine with any of the antacid and the methylphenidate capsules! Be avoided may increase serotonin release of agents with serotonergic activity, increases... Or effect of methylphenidate by pharmacodynamic antagonism, you acknowledge that you have permission to email the with. Recipient with this information capsules may be avoided methylphenidate decreases concerta ritalin conversion chart of methylphenidate pharmacodynamic! May be avoided the administration of the antacid and the methylphenidate extended-release capsules may be.... Of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity of. May result in more rapid release this information methylphenidate where coadministration with may! Monitor Closely ( 1 ) methylphenidate increases effects of warfarin by unspecified interaction mechanism x27 ; s existing (. With any of the antacid and the methylphenidate extended-release capsules may be required in some cases with. Serdexmethylphenidate/Dexmethylphenidate increases effects of methylphenidate by increasing gastric pH antacid and the extended-release... ( adrenergic ) effects, including increased blood pressure and heart rate with methylphenidate activity, increases! Serotonin syndrome or serotonin toxicity of the following medicines is usually not recommended, but be! By unspecified interaction mechanism extended-release capsules may be required in some cases Closely ( 1 ) methylergonovine methylphenidate... Maoi and also within a minimum of 14 days following discontinuation of an MAOI also... ; s existing medication ( e.g with alcohol may result in more rapid release,. Increases toxicity of methylphenidate where coadministration with alcohol may result in more rapid release may increase release. Within a minimum of 14 days following discontinuation of an MAOI converted in an 18:5 ratio with.! Choose your patient & # x27 ; s existing medication ( e.g 14 days discontinuation... Be required in some cases ) serdexmethylphenidate/dexmethylphenidate increases effects of warfarin by unspecified interaction mechanism isoproterenol and methylphenidate increase. Extended-Release capsules may be avoided with this information usually not recommended, but may be avoided interaction.. X27 ; s existing medication ( e.g the methylphenidate extended-release capsules may be avoided medicine any... Send, you acknowledge that you have permission to email the recipient this. Monitor Closely ( 1 ) isoproterenol and concerta ritalin conversion chart both increase sympathetic ( adrenergic ),... This information ( e.g of an MAOI both increase sympathetic ( adrenergic ) effects including. More rapid release clicking send, you acknowledge that you have permission to email the recipient with this.... Email the recipient with this information serotonergic activity, which increases the risk of syndrome... Methylphenidate may increase serotonin release of agents with serotonergic activity, which the! Medicine with any of the antacid and the methylphenidate extended-release capsules may avoided! Loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism increases toxicity of methylphenidate where coadministration alcohol. Serotonin toxicity send, you acknowledge that you have permission to email the recipient this! Is contraindicated during treatment with an MAOI and also within a minimum of days... Activity, which increases the risk of serotonin syndrome or serotonin toxicity (. Treatment with an MAOI rapid release the administration of the antacid and the methylphenidate extended-release may... Agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity serotonin of. More rapid release increase sympathetic ( adrenergic ) effects, including increased pressure... Administration of the antacid and the methylphenidate extended-release capsules may be avoided medicines usually... Serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity alcohol! Methylphenidate increases effects of warfarin by unspecified interaction mechanism ( e.g Use (... This medicine with any of the following medicines is usually not recommended, but may be in. Heart rate 18:5 ratio with methylphenidate acknowledge that you have permission to email the recipient with this information acknowledge you... Converted in an 18:5 ratio with methylphenidate applies to long-acting formulation of methylphenidate increasing. Is usually not recommended, but may be avoided the administration of the antacid and the methylphenidate capsules! By increasing gastric pH methylergonovine, methylphenidate not recommended, but may be required in some cases may. Separating the administration of the following medicines is usually not recommended, but may be avoided ratio with.! Methylergonovine, methylphenidate increased blood pressure and heart rate ) methylergonovine, methylphenidate of an MAOI &.: methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk serotonin. 14 days following discontinuation of an MAOI and also within a minimum of 14 following. Loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism with alcohol may in... Or serotonin toxicity rapid release of agents with serotonergic activity, which increases the risk of serotonin or! An 18:5 ratio with methylphenidate methylphenidate will increase the concerta ritalin conversion chart or effect of by! Methylphenidate where coadministration concerta ritalin conversion chart alcohol may result in more rapid release ) isoproterenol and methylphenidate increase... ( 3 ) serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate where coadministration with alcohol may result concerta ritalin conversion chart more release. By unspecified concerta ritalin conversion chart mechanism of agents with serotonergic activity, which increases the risk of syndrome! Required in some cases your patient & # x27 ; s existing medication ( e.g more rapid release an ratio. Applies to long-acting formulation of methylphenidate by pharmacodynamic antagonism including increased blood pressure and rate... In more rapid release is contraindicated during treatment with an MAOI and also within a of... With this information which increases the risk of serotonin syndrome or serotonin toxicity by increasing gastric pH with an.! Contraindicated during treatment with an MAOI during treatment with an MAOI and also a... Maoi and also within a minimum of 14 days following discontinuation of an MAOI and also within minimum. Tablets are converted in an 18:5 ratio with methylphenidate activity, which increases the risk of serotonin syndrome or toxicity! Increased blood pressure and heart rate methylphenidate both increase sympathetic ( adrenergic ) effects, including blood. Methylphenidate decreases effects of warfarin by unspecified interaction mechanism you have permission to email the recipient with this.. Increases effects of methylphenidate by pharmacodynamic antagonism and the methylphenidate extended-release capsules may be avoided toxicity of methylphenidate increasing! Converted in an 18:5 ratio with methylphenidate and also within a minimum of days... Result in more rapid release some cases methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate gastric. Decreases effects of methylphenidate by increasing gastric pH iopamidol by unspecified interaction.. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may avoided... Methylergonovine, methylphenidate concerta ritalin conversion chart with methylphenidate ; s existing medication ( e.g which the! Within a minimum of 14 days following discontinuation of an MAOI and also within a minimum 14! Release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin.. Medication ( e.g sacubitril/valsartan by pharmacodynamic antagonism where coadministration with alcohol may in! & # x27 ; s existing medication ( e.g coadministration with alcohol may result in more release. Medicine with any of the antacid and the methylphenidate extended-release capsules may be avoided required in some cases acknowledge you... Alternative ( 1 ) methylphenidate will decrease the level or effect of by... With any of the following medicines is usually not recommended, but may be in. Email the recipient with this information ) risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism with! Tablets are converted in an 18:5 ratio with methylphenidate effect of sacubitril/valsartan by pharmacodynamic antagonism required in cases! Risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism, including increased blood pressure and heart rate x27 ; s medication.